NCT06509477View on ClinicalTrials.gov

Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management

NACompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

November 11, 2023

Study Completion Date

November 11, 2023

Conditions
Moderate or Severe Nasolabial Folds
Interventions
DEVICE

Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)

Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion

DEVICE

Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)

Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion

Trial Locations (1)

19947-66411

Orchid Pharmed, Medical Department, Tehran

All Listed Sponsors
lead

Espad Pharmed

INDUSTRY

NCT06509477 - Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management | Biotech Hunter | Biotech Hunter